Episode Details
Back to Episodes
Pharmaceutical Executive Daily: September 23, 2025
Published 7 months, 4 weeks ago
Description
In today’s Pharmaceutical Executive Daily, we cover GSK’s supplemental application to update the label for Leucovorin, the FDA’s complete response letter to Otsuka and Lundbeck’s sNDA for Rexulti, and the medical community’s response to former President Trump’s claims linking Tylenol use to autism risk.